What is Zenith Epigenetics?
Zenith Epigenetics operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of bromodomain and extra-terminal inhibitors, commonly referred to as BETi. The company occupies a specialized niche in the oncology sector, focusing on the translation of complex bromodomain biology into targeted therapeutic interventions. Their primary asset, ZEN-3694, represents a significant advancement in the field, currently undergoing rigorous clinical evaluation to determine its efficacy in overcoming drug resistance across various cancer indications. Through strategic collaborations with leading oncology research institutions, Zenith Epigenetics is actively refining combination therapy models designed to improve patient outcomes and redefine standard-of-care practices in high-unmet-need environments.
How much funding has Zenith Epigenetics raised?
Zenith Epigenetics has raised a total of $12.3M across 2 funding rounds:
Unspecified
$8M
Private Equity
$4.3M
Unspecified (2014): $8M, investors not publicly disclosed
Private Equity (2014): $4.3M, investors not publicly disclosed
Key Investors in Zenith Epigenetics
Undisclosed Investor
An institutional capital provider focused on long-term growth and strategic development within the life sciences sector.
Undisclosed Investor
A specialized investment firm providing essential backing for early-to-mid stage clinical biotechnology companies.
Undisclosed Investor
A strategic partner dedicated to financing innovative research and development in the field of targeted cancer therapies.
What's next for Zenith Epigenetics?
With the recent influx of capital, Zenith Epigenetics is poised to transition into a more mature phase of clinical operations. The strategic roadmap likely involves the expansion of phase-specific trials for ZEN-3694 and the potential diversification of its therapeutic portfolio. As the company continues to navigate the complexities of drug development, the focus will remain on achieving key clinical milestones that validate their BETi platform. Investors and industry stakeholders will be monitoring the firm's ability to translate these scientific advancements into scalable, market-ready solutions, effectively positioning Zenith as a pivotal player in the next generation of targeted cancer therapeutics.
See full Zenith Epigenetics company page
